GlaxoSmithKline agreed to acquire Nuvalent for approximately $11 billion to expand its oncology pipeline with two late-stage lung cancer treatments. The move aims to counter patent cliffs on HIV drugs
GSK acquired US cancer firm Nuvalent for $10.6bn in its largest deal since 2014. The purchase adds two late-stage lung cancer drugs to GSK's pipeline, pending FDA approval later this year.
US stock futures climbed as chip stocks extended gains and Middle East hostilities eased, causing oil prices to fall over 2%. GSK also agreed to acquire cancer drug developer Nuvalent for $10.6 billio
GSK announced plans to acquire Nuvalent for $10.6 billion, aiming to expand its small-molecule kinase inhibitor portfolio for treatment-resistant cancers under new CEO Luke Miels.
British drugmaker GSK agreed to acquire U.S. cancer developer Nuvalent for $10.6 billion to expand its lung cancer portfolio. The all-cash deal values Nuvalent at $124 per share and is expected to con
UK pharmaceutical group GSK is in talks to acquire cancer biotech Nuvalent for over $9 billion, aiming to expand its product pipeline. The potential deal reflects a broader biopharma M&A frenzy projec
ChemBrief